title: ScreenPro FH - Screening Project for Familial Hypercholesterolemia in Central, Southern and Eastern Europe: Rationale and Design.
abstract: Familial hypercholesterolemia (FH) is a genetic disorder with well-known genetic transmission and clinical course. Despite great recent progress, FH is still underestimated, under-diagnosed and thus undertreated. Furthermore it represents a significant healthcare challenge as a common risk factor for the premature development of coronary heart disease. The ScreenPro FH Project is an international network project aiming at improving complex care - from timely screening, through diagnosis to up-to-date treatment of familial hypercholesterolemia in Central, Eastern and Southern Europe. An important task for the project is to harmonise and unify diagnostic and therapeutic approaches in participating countries, where the situation differs from country to country. Countries with more experience should serve as a model for countries developing the FH network.Key words: diagnosis - familial hypercholesterolemia - screening - treatment optimization.
authors.forename: Richard
authors.initials: R
authors.lastname: Češka
authors.forename: György
authors.initials: G
authors.lastname: Paragh
authors.forename: Željko
authors.initials: Ž
authors.lastname: Reiner
authors.forename: Maciej
authors.initials: M
authors.lastname: Banach
authors.forename: Lale
authors.initials: L
authors.lastname: Tokgözoğlu
authors.forename: Andrey V
authors.initials: AV
authors.lastname: Susekov
authors.forename: Katarína
authors.initials: K
authors.lastname: Rašlová
authors.forename: Tomáš
authors.initials: T
authors.lastname: Freiberger
authors.forename: Branislav
authors.initials: B
authors.lastname: Vohnout
authors.forename: Andrzej
authors.initials: A
authors.lastname: Rynkiewicz
authors.forename: Assen
authors.initials: A
authors.lastname: Goudev
authors.forename: Gheorghe-Andrei
authors.initials: GA
authors.lastname: Dan
authors.forename: Dan
authors.initials: D
authors.lastname: Gaiţă
authors.forename: Belma
authors.initials: B
authors.lastname: Pojskić
authors.forename: Ivan
authors.initials: I
authors.lastname: Pećin
authors.forename: Meral
authors.initials: M
authors.lastname: Kayıkçıoğlu
authors.forename: Olena
authors.initials: O
authors.lastname: Mitchenko
authors.forename: Marat V
authors.initials: MV
authors.lastname: Ezhov
authors.forename: Gustavs
authors.initials: G
authors.lastname: Latkovskis
authors.forename: Žaneta
authors.initials: Ž
authors.lastname: Petrulionienė
authors.forename: Zlatko
authors.initials: Z
authors.lastname: Fras
authors.forename: Nebojsa
authors.initials: N
authors.lastname: Tasić
authors.forename: Erkin M
authors.initials: EM
authors.lastname: Mirrakhimov
authors.forename: Tolkun
authors.initials: T
authors.lastname: Murataliev
authors.forename: Alexander B
authors.initials: AB
authors.lastname: Shek
authors.forename: Vladimír
authors.initials: V
authors.lastname: Tuka
authors.forename: Alexandros D
authors.initials: AD
authors.lastname: Tselepis
authors.forename: Elie M
authors.initials: EM
authors.lastname: Moubarak
authors.forename: Khalid Al
authors.initials: KA
authors.lastname: Rasadi
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001781:Blood Component Removal; D003327:Coronary Disease / Q000453:epidemiology; D005060:Europe / Q000453:epidemiology; D005061:Europe, Eastern / Q000453:epidemiology; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy; D008403:Mass Screening; D012307:Risk Factors
chemical_list: D000924:Anticholesteremic Agents